This is a published notice on the Find a Tender service: <a href="https://www.find-tender.service.gov.uk/Notice/010544-2025">https://www.find-tender.service.gov.uk/Notice/010544-2025</a>

**Planning** 

# NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025

NHS England

UK2: Preliminary market engagement notice - Procurement Act 2023 - <u>view information</u> <u>about notice types</u>

Notice identifier: 2025/S 000-010544

Procurement identifier (OCID): ocds-h6vhtk-04f708

Published 21 March 2025, 8:19am

#### Scope

#### Reference

C346388

### **Description**

Provision of Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of; • neovascular (wet) agerelated macular degeneration (AMD) • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) • proliferative diabetic retinopathy (PDR) • visual impairment due to diabetic macular oedema (DME) • visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy • vision impairment associated with chronic diabetic macular oedema, (DME) • visual impairment due to myopic choroidal neovascularisation (myopic CNV) • retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP

(aggressive posterior ROP) disease • inflammation of the posterior segment of the eye presenting as non-infectious uveitis • prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye

#### **Commercial tool**

Establishes a framework

#### **Total value (estimated)**

- £1,516,353,164 excluding VAT
- £1,819,623,796 including VAT

Above the relevant threshold

### **Contract dates (estimated)**

- 1 December 2025 to 31 May 2027
- Possible extension to 31 May 2029
- 3 years, 6 months

## Main procurement category

Goods

#### **CPV** classifications

- 33600000 Pharmaceutical products
- 33690000 Various medicinal products

#### **Contract locations**

• UK - United Kingdom

## **Engagement**

#### **Engagement deadline**

11 April 2025

#### **Engagement process description**

NHS England is pleased to invite suppliers to a virtual 1:1 preliminary market engagement meeting in relation to the upcoming re-tender of the Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines Framework. The purpose of the sessions is to update suppliers regarding timelines and to discuss product details, product launches during the proposed framework period, tender structure, clinical aspects and KPI's. Please contact <a href="mailto:b.kullootee@nhs.net">b.kullootee@nhs.net</a> or <a href="mailto:michelle.clarke6@nhs.net">michelle.clarke6@nhs.net</a> to register your interest. There will also be a 7 day window for queries to be raised in writing after all sessions have concluded.

# **Participation**

# Particular suitability

Small and medium-sized enterprises (SME)

## **Submission**

## Publication date of tender notice (estimated)

2 June 2025

# **Contracting authority**

#### **NHS England**

• Public Procurement Organisation Number: PDPT-3135-BWWY

Wellington House, 133-135 Waterloo Rd

London

SE1 8UG

**United Kingdom** 

Contact name: NHS England

Email: b.kullootee@nhs.net

Website: <a href="https://www.england.nhs.uk/">https://www.england.nhs.uk/</a>

Region: UKI45 - Lambeth

Organisation type: Public authority - central government